Month: October 2022
-
Gut-Brain Meds Developer Going Public in Merger
31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, in a deal expected to…
-
Infographic – US Public Supports Govt Science Spending
Most Americans believe the U.S. should be the world leader in scientific achievement, and support continued U.S. government investments in science.
-
AI Analytics Boost Breast Cancer Assessment Diversity
A genomic analytics company says an ethnicity algorithm added to a personal health questionnaire improves risk assessments for breast cancer across all populations.
-
Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors
Research with lab animals shows an experimental cancer vaccine generates immune-system cells that infiltrate solid tumors and reduce the tumor’s protective environment.
-
Trial Shows Antibody Neutralizes, Reduces HIV Virus
Results from a clinical trial show an experimental one-time antibody therapy, even at low doses, lowers levels of HIV virus in people living with the disease.
-
Immunotherapy Start-Up Launches Collaboration, Raises $65M
A new biotechnology company is creating cancer immunotherapies that it says harness more of the full power of T-cells in the immune system to attack tumors.
-
Grant Funds Regenerative Gel for Treating Skin Ulcers
A California state research agency is funding preclinical development of a gel designed to regenerate stem cells in the skin to help heal venous skin ulcers.
-
Infographic – Q3 Digital Health Venture Funds Slide
Venture funding for start-ups worldwide applying digital technologies to health care continued to fall in the third quarter of 2022, both in deals and dollars invested.
-
New Funds Awarded for Rapid Infection Diagnostics
A developer of faster infection diagnostics is receiving another $8.2 million from an international group supporting solutions to antibiotic resistant microbes.
-
Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised
A clinical trial is underway testing a synthetic antibody designed to prevent SARS-CoV-2 viral infections in people with compromised immune systems.